Cancer Immunology Community Seeks Better End Points
November 29, 2016
Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
Continue reading here.
With a call of 130 decibels, the bare-throated bellbird is a big-beaked marvel.
Autonomous blood-drawing devices could help address phlebotomist shortages.